Valneva (VALN) to Release Earnings on Wednesday

Valneva (NASDAQ:VALN) is expected to be releasing its earnings data before the market opens on Wednesday, March 19th. Analysts expect Valneva to post earnings of ($0.22) per share and revenue of $55.64 million for the quarter.

Valneva Trading Up 0.1 %

NASDAQ VALN opened at $6.80 on Monday. Valneva has a 1-year low of $3.62 and a 1-year high of $9.50. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. The stock has a 50-day moving average of $6.11 and a 200-day moving average of $5.60. The firm has a market cap of $552.57 million, a PE ratio of -52.31 and a beta of 1.93.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $17.00 target price on shares of Valneva in a research note on Friday, February 28th.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.